内容概要：纺织原材料检测是纺织产业链的"第一道防线"，对纺织品的设计、生产和应用具有重要影 响，其技术水平和标准完善度直接影响纺织品的质量竞争力和市场认可度。纺织原材料检测对于保障纺 织品的质量和满足消费者需求至关重要。近年来，随着国内对纺织品质量与安全的日益关注，原材料检 测行业的市场需求呈现出持续增长的态势。2024年，我国纺织原材料检测报告数量21.16万份，较2023 年增加0.49万份；市场规模达到433亿元，较2023年增加5亿元；预计2025年，我国纺织原材料检测报告 数量21.75万份，市场规模达到439亿元。随着消费者对"安全、功能、环保"的需求提升，检测技术将向 快速化（如近红外在线检测）、精准化（如分子级成分分析）方向升级，近年来，纺织原材料检测市场 均价呈增长趋势。2024年，我国纺织原材料检测市场均价从2016年的425元/份增长至489元/份，预计 2025年将达到495元/份。 上市企业：中纺标（873122）、CTI华测检测（300012）、天纺标（871753）、华测检测（300012） 纺织原材料检测标准是确保纺织原材料符合特定要求的指南和规范，这些标准涵盖了纺织原材料的性 ...

证券研究报告 | 2025 年 09 月 04 日 晨会集萃 制作：产品中心 风险提示：经济景气度恢复偏慢、货币政策呵护力度不够、测算与现实情 况存在偏差。 《环保公用|皖能电力（000543）：煤价下行带动盈利能力提升，新投产机 组贡献增量》 公司披露2025 年中报。上半年公司实现营收131.85 亿元，同比下降5.83%； 实现归母净利润 10.82 亿元，同比增长 1.05%。1、新机组投产贡献增量， 部分对冲存量机组量价下滑影响。电价方面，安徽省 2025 年度双边协商 交易成交电量 1067.04 亿千瓦时，成交加权均价为 412.97 元/兆瓦时，同 比下降 5.35%。电量方面，安徽省上半年火电发电量为 1383.5 亿千瓦时， 同比下降 7.9%，公司存量机组发电量或有所下滑。2、煤价下行带动盈利 能力提升，H1 毛利率同比提高 4.06pct。燃料成本下降带动公司营业成本 降低，上半年公司营业成本为 110.43 亿元，同比下降 10.18%。上半年公 司实现毛利率 16.25%，同比提高 4.06 个百分点。综合来看，公司上半年 实现净利率 12.30%，同比提高 1.65 个百分点；实 ...

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6]. Core Views - The company reported a revenue of 2.96 billion yuan for the first half of 2025, representing a year-on-year growth of 6.05%, and a net profit attributable to shareholders of 467 million yuan, up 7.03% year-on-year [1]. - The gross margin and net margin for the first half of 2025 were 49.59% and 15.69%, respectively, showing slight improvements compared to the previous year [1]. - The company is actively pursuing strategic acquisitions and international expansion, which is expected to inject long-term growth momentum into its future development [4]. Financial Performance Summary - For Q2 2025, the company achieved a revenue of 1.673 billion yuan, a year-on-year increase of 4.62% and a quarter-on-quarter increase of 30.03%. The net profit for the same period was 331 million yuan, up 8.89% year-on-year and 143.10% quarter-on-quarter [1]. - The revenue breakdown for the first half of 2025 by product segments includes: Life Sciences Testing (1.273 billion yuan, +1.11%), Industrial Products Testing (601 million yuan, +7.47%), Consumer Products Testing (522 million yuan, +13.15%), Trade Assurance Testing (426 million yuan, +13.48%), and Pharmaceutical Industry (137 million yuan, +1.30%) [2]. - The company expects net profits for 2025 to reach 1.03 billion yuan, reflecting a year-on-year growth of 11.79% [4]. Segment Performance - The Life Sciences segment is enhancing operational efficiency and maintaining steady growth, with a focus on deepening customer demand in the agricultural testing field [3]. - The company is performing well in the electronic materials chemistry and reliability sectors, with a strategic acquisition of Microlab Tech planned for 2024 to enhance its PCB testing capabilities [3]. - The Consumer Products segment is showing good growth, particularly in light industry and toys, while the automotive testing sector is experiencing improvements [3]. - The Medical and Pharmaceutical segment is expected to see positive growth, with a focus on expanding laboratory investments [4]. Financial Projections - The company’s projected revenues for 2025 to 2027 are 6.622 billion yuan, 7.316 billion yuan, and 8.002 billion yuan, respectively, with growth rates of 8.85%, 10.47%, and 9.38% [5]. - The projected net profit for 2025 is 1.03 billion yuan, with an expected growth rate of 11.79% [5]. Valuation Metrics - The company is expected to have a P/E ratio of 21, 19, and 17 for the years 2025, 2026, and 2027, respectively [4]. - The projected P/B ratio is expected to decrease from 3.50 in 2023 to 2.31 in 2027 [5].

9月3日，华测检测盘中下跌2.05%，截至13:53，报12.91元/股，成交3.06亿元，换手率1.63%，总市值 217.25亿元。 华测检测所属申万行业为：社会服务-专业服务-检测服务。所属概念板块包括：CDM概念、京津冀、 MSCI中国、碳中和、基金重仓等。 截至6月30日，华测检测股东户数8.11万，较上期增加4.53%；人均流通股17647股，较上期减少4.34%。 2025年1月-6月，华测检测实现营业收入29.60亿元，同比增长6.05%；归母净利润4.67亿元，同比增长 7.03%。 分红方面，华测检测A股上市后累计派现10.77亿元。近三年，累计派现4.36亿元。 机构持仓方面，截止2025年6月30日，华测检测十大流通股东中，香港中央结算有限公司位居第一大流 通股东，持股2.69亿股，相比上期增加786.79万股。易方达创业板ETF（159915）位居第三大流通股 东，持股3491.97万股，相比上期减少91.31万股。南方中证500ETF（510500）位居第四大流通股东，持 股2494.45万股，相比上期增加351.16万股。嘉实新兴产业股票（000751）位居第八大流通股东，持股 ...

人民财讯9月3日电，企查查APP显示，近日，广西河池品晟生物科技有限公司成立，注册资本1000万 元，经营范围包含：动物诊疗；国家重点保护陆生野生动物人工繁育；省级重点保护陆生野生动物人工 繁育；实验动物生产等。企查查股权穿透显示，该公司由华测检测全资持股。 转自：证券时报 ...

事件描述 公司发布2025 年中报，2025H1 实现营收29.60 亿元，同增6.05%；实现归母净利润4.67 亿元，同增 7.03%；实现扣非归母净利润4.39 亿元，同增9.08%。 现金流表现亮眼，首次推出中期分红，有望持续增加投资者回报。 2025H1，公司加强现金流管控，经营活动产生的现金流量净额1.75 亿元，同比增长686.93%。同时，在 投资者回报方面，公司今年增加中期分红，随着后续基地建设逐步收尾、固定资产投资比例结合实际情 况下修，公司股息率有望逐步提高。 盈利预测与估值 预计公司2025-2027 年营收分别为65.51、71.45、77.40 亿元，同比增速分别为7.67%、9.07%、8.33%； 归母净利润分别为10、11.04、12.16 亿元，同比增速分别为8.57%、10.39%、10.16%。公司2025-2027年 业绩对应PE 估值分别为22.73、20.59、18.69，维持"买入"评级。 风险提示： 各板块业务均实现稳健增长。分板块来看，2025H1 生命科学板块实现营业收入12.73 亿元，同比增长 1.11%；消费品测试板块实现营业收入5.22 亿元，同比 ...

近期，上市公司2025年半年报进入密集披露期。据仪表网统计显示，截至8月29日，已有50家上市仪器 仪表公司披露了2025年中报。50家公司上半年度实现总营收约659.65亿元，实现归母净利润约87.35亿 元。其中，上半年营业收入出现增长的有40家，增幅在20%以上的有14家；上半年归母净利润出现增长 的有34家，增幅在50%以上的有10家。 从营业收入来看，2025年上半年度营业收入超过10亿元的有14家，分别为汇川技术205.09亿元、三星医 疗79.72亿元、川仪股份32.81亿元、华测检测29.6亿元、科陆电子25.73亿元、林洋能源24.8亿元、高德 红外19.34元、海兴电力19.24亿元、金卡智能15.39亿元、威胜信息13.68亿元、聚光科技12.95亿元、海 得控制12.8亿元、汉威科技11.77亿元、苏奥传感11亿元。营收增幅在50%以上的有3家，分别是苏奥传 感增长99.2%、高德红外增长68.24%、汇中股份增长51.67%。 从归母净利润来看，2025年上半年度归母净利润在1亿元以上的有16家，其中净利润最高的分别为汇川 技术29.68亿元，三星医疗12.30亿元。归母净利润增幅在 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本届荣获金麒麟·金牌董秘称号的华测检测董秘姜华，正是这一群体中的杰出代表。该荣誉不仅体现了 其个人在资本沟通、合规治理与战略协同方面的卓越能力，也反映了市场和投资者对华测检测治理水平 与价值成长的高度认可。 MACD金叉信号形成，这些股涨势不错！ 责任编辑：郭栩彤 9月1日，第十一届新浪财经金麒麟·金牌董秘榜单正式揭晓。在本次备受瞩目的评选中，华测检测董事 会秘书姜华凭借卓越的专业能力和出色的工作表现荣耀加冕，荣获第十一届金麒麟·金牌董秘责任先锋 奖。 作为上市公司与资本市场之间的"关键纽带"，董秘在企业治理与发展中扮演着多重角色：他们既是公司 规范运作的"守门人"，也是资本战略的"参谋者"；既是信息披露的"发言人"，也是投资者关系的"架构 师"。秉持"寻找A股最佳资本品牌代言人"的初心，新浪财经金麒麟·金牌董秘评选已成功举办十一届， 累计评选出优秀金牌董秘900余人次，成为业内高度认可、影响力广泛的权威奖项之一。该评选不仅着 眼于信息披露质量、投资者沟通成效，更综合考量其在公司治理、ESG建设、资本运作等多维度的贡 献。 一位优秀的董秘，能在复杂的市场环境中 ...

Core Viewpoint - The company reported a steady growth in revenue and net profit for the first half of 2025, indicating resilience in its operations and a positive outlook for the second half of the year [1][2][3]. Financial Performance - In H1 2025, the company achieved revenue of 2.96 billion yuan, a year-on-year increase of 6.05%, and a net profit attributable to shareholders of 467 million yuan, up 7.03% year-on-year [1]. - For Q2 2025, the company recorded revenue of 1.673 billion yuan, a year-on-year increase of 4.62%, and a net profit of 331 million yuan, up 8.9% year-on-year, showing acceleration compared to Q1 [2]. - The company's gross margin and net margin for H1 2025 were 49.59% and 15.69%, respectively, reflecting slight improvements year-on-year [3]. Segment Performance - Revenue growth was notable in the consumer testing and trade assurance segments, with respective increases of 13.15% and 13.48% year-on-year [2]. - The revenue contributions from various segments in H1 2025 were as follows: Life Sciences (1.273 billion yuan, 43.02%), Industrial Testing (601 million yuan, 20.31%), Consumer Testing (522 million yuan, 17.64%), Trade Assurance (426 million yuan, 14.39%), and Medical Services (137 million yuan, 4.64%) [2]. Strategic Initiatives - The company is focusing on its "123 strategy" to enhance service quality and innovation, aiming for accelerated revenue and profit growth in H2 2025 [3]. - The internationalization process is advancing, with overseas revenue accounting for 7.3% of total revenue, an increase of 0.89 percentage points year-on-year [4]. - The company is pursuing several acquisitions to enhance its service capabilities and expand its international presence, including agreements with prominent investment firms and service providers in South Africa and the EU [4]. Future Outlook - The company is projected to achieve revenues of 6.71 billion yuan, 7.396 billion yuan, and 8.158 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 1.036 billion yuan, 1.149 billion yuan, and 1.274 billion yuan [5]. - The company is expected to maintain a strong strategic adjustment capability in response to downstream demand changes, further enhancing its resilience against risks [5].

Group 1 - The report aims to summarize important in-depth reports, significant commentary, and marginal changes within the macro strategy team of large manufacturing [1] - Key companies highlighted include Shanghai Yanpu, Honghe Precision, Zhenlan Instrument, Zhejiang Rongtai, Sany Heavy Industry, China Shipbuilding, Huace Testing, Xugong Machinery, Hangcha Group, Yaxing Anchor Chain, Robotech, Juxing Technology, Yadea Holdings, Aima Technology, Hongdu Aviation, Zhongji United, and BGI [2][3] Group 2 - The mechanical equipment sector emphasizes investment opportunities in leading engineering machinery companies, with a continuous push for humanoid robots and overseas expansion [4] - As of August 22, 2025, the best-performing indices in the large manufacturing sector included the Sci-Tech Innovation 50 (+13%), the Semiconductor Index (+12%), and the ChiNext Index (+6%) [5][21] Group 3 - Zhongji United's mid-year report met expectations, with a 87% year-on-year increase in net profit attributable to shareholders for the first half of 2025 [8] - The company has significantly improved its profitability, with a sales net profit margin increasing by 8 percentage points year-on-year in Q2 2025 [8] - The wind power sector is experiencing high demand, with domestic wind power installations expected to reach approximately 105-115 GW in 2025, indicating a strong growth trajectory [9] Group 4 - Jinwo Co. reported a 94% year-on-year increase in net profit for the first half of 2025, driven by growth in its screw and insulation shaft sleeve segments [9] - The company is focusing on upgrading production capacity and enhancing its international layout through a planned fundraising of up to 950 million yuan [9] - The humanoid robot industry is anticipated to explode, with the market expected to grow significantly, driving demand for high-precision CNC machine tools [11]